Evaluation of interleukin-29 in autoimmune and inflammatory thyroid diseases.

Bogusz Falkowski Ewelina Szczepanek-ParulskaAleksandra KrygierElzbieta WrotkowskaMarek Ruchala

Published in: Clinical endocrinology (2021)

This is the first study to demonstrate elevated IL-29 serum levels in patients with GD. Our results suggest that IL-29 might be engaged in one of the pathogenetic pathways of GD, but no HT and SAT. Future studies are required to evaluate the potential of the protein as a therapeutic target in GD.

Keyphrases

multiple sclerosis
oxidative stress
current status
risk assessment
binding protein
drug induced